Effect of Dose Modifications on Response to Duvelisib in Patients With Relapsed/Refractory CLL/SLL in the Duo Trial

Hematological Oncology - United Kingdom
doi 10.1002/hon.30_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Patterns of Duvelisib-Induced Lymphocytosis in Patients With R/R CLL or SLL Including Those With High-Risk Factors Treated in the Duo Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Characterization of Duvelisib in Patients With Refractory Marginal Zone Lymphoma: Data From the Phase 2 Dynamo Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Efficacy of Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

The PI3Kδ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood Cancer Journal
OncologyHematology
2015English

Real-World Results of Ibrutinib in Relapsed/Refractory CLL in France: Early Results on a Large Series of 428 Patients

American Journal of Hematology
Hematology
2017English

Ibrutinib for Relapsed / Refractory Cll: An Update of the Uk and Ireland Analysis of Outcomes in 315 Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (Cll) Relapsed or Refractory in Argentina

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy